European Commission Approves Pfizer’s DURVEQTIX® (fidanacogene elaparvovec), a One …

European Commission Approves Pfizer’s DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B. Thursday, July 25, …Read More